CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...